Press Release Archive
Press Releases
June 2019
06.12.2019 Medicines Research Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor 06.05.2019 Leadership Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development
May 2019
05.24.2019 Medicines Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures 05.17.2019 Medicines Pfizer confirms initiation of EU review of Tofacitinib with interim recommendations 05.15.2019 Research Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting 05.15.2019 Research Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis 05.14.2019 Medicines FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma 05.09.2019 Finance Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts 05.08.2019 Finance Pfizer Acquires Clinical-Stage Biotech Therachon 05.07.2019 Medicines European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer 05.06.2019 Medicines U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
April 2019
04.30.2019 Finance PFIZER REPORTS FIRST-QUARTER 2019 RESULTS
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.